Investor Moves
| Investor | Portfolio Value | Portfolio Change | Position Change | Avg Buy Price | Current Price |
|---|---|---|---|---|---|
Steven CohenPoint72 $7.0M967.6k shares AddQ1 2026 $1.6M $7.24 $7.18 | |||||
Ken GriffinCitadel Advisors $-108.0K ExitQ3 2025 $108k -- $7.18 | |||||
Ken GriffinCitadel Advisors $68.5K AddQ2 2025 $69k -- $7.18 | |||||
News
globenewswire.comEupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conferenceglobenewswire.comMay 28
globenewswire.comEupraxia Pharmaceuticals Reports First Quarter 2026 Financial Resultsglobenewswire.comMay 12
globenewswire.comEupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Weekglobenewswire.comMay 6
globenewswire.comEupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)globenewswire.comMay 5
globenewswire.comEupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officerglobenewswire.comMay 1